A Phase 3 Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management
Phase of Trial: Phase III
Latest Information Update: 12 Mar 2017
At a glance
- Drugs Tolvaptan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms SECRET of CHF
- 12 Mar 2017 Primary endpoint (Change in self-assessed dyspnea score, assessed at 8 and 16 h, by a 7-point Likert scale) has not been met, according to results published in the Journal of the American College of Cardiology.
- 12 Mar 2017 Results published in the Journal of the American College of Cardiology.
- 26 Sep 2016 Status changed from recruiting to completed.